On the BSE, the stock was quoting at Rs 2,480, bouncing back 20 per cent from its intra-day low of Rs 2,065. The trading volumes on the counter jumped three-fold with a combined 4.11 million equity shares changed hands on the NSE and BSE so far.
On February 8, 2019, Dr Reddy’s Laboratories informed the stock exchanges that the US Food and Drug Administration (USFDA) has issued form 483 with 11 observations for its manufacturing-3 facility at Bachupally in Hyderabad. The company said it will address them comprehensively within the stipulated timeline.
Analysts at the firm wrote that, among the observations issued, two of them are related to lack of space as well as drains. It has termed one of the observations relating to facility structure being negative. Going forward, the company’s response to the US FDA letter will hold the key, according to a CNBC-TV18